AI Matchmaking
An AI-driven partnering platform opens four weeks before the event - filter delegates by asset type, capacity need, or service capability and request the meetings that matter.
About ADC NEXUS 2027
Scientific innovation alone is no longer enough
Antibody-Drug Conjugates have become one of the fastest-growing and most transformative modalities in modern oncology. Yet as the clinical pipeline expands and approvals accelerate worldwide, the industry has reached a turning point: scientific breakthroughs now depend on the ability to manufacture, scale, transfer, and deliver increasingly complex therapies with speed, precision, and regulatory confidence.
ADC NEXUS 2027 was created to meet that moment - the industry's premier platform dedicated entirely to the operational and commercial success of antibody-drug conjugates. Unlike traditional conferences centred on discovery and preclinical science, it is built around the complete manufacturing and commercialization ecosystem, spanning every stage of the ADC lifecycle.
Every stage of the ADC lifecycle
- 01Process development
- 02CMC strategy
- 03Bioconjugation
- 04Aseptic manufacturing
- 05Sterile fill-finish
- 06Technology transfer
- 07Quality systems
- 08Regulatory compliance
- 09Global supply chain
- 10Commercial production
As capacity tightens and development timelines compress, the organizations that win will be the ones that turn conversations into collaborations.
They build the strongest partnerships, adopt the right technologies, and stand up resilient global supply networks. ADC NEXUS is the environment where those relationships form - and where they evolve into long-term commercial partnerships.
More than a conference
ADC NEXUS is a global business marketplace - where innovators meet manufacturers, developers meet solution providers, and the future of ADC manufacturing is shaped through collaboration. Whether you are developing breakthrough therapeutics, expanding capacity, delivering enabling technologies, or supporting commercialization, it is an unmatched opportunity to connect with the people, organizations, and ideas defining the next generation of antibody-drug conjugates.
Business Partnering
A commercial marketplace, not an academic conference
Business partnering is the engine of ADC NEXUS. Every format is engineered to put the right developers, CDMOs, and solution providers in the same room - and to turn conversations into contracts. It is what sets the summit apart.
Private Meeting Rooms
Dedicated on-site rooms for confidential, focused 30-minute meetings - real conversations, not crowded booth small-talk.
Hosted Buyer Program
Qualified biopharma buyers are hosted and curated, so partners are guaranteed face time with genuine decision-makers.
Procurement Meetings
Direct access to procurement and supply-chain teams actively sourcing fill-finish capacity, outsourcing, and services.
CDMO Matchmaking
Developers matched to CDMOs by capability, capacity, and modality fit - engineered introductions, not chance encounters.
Executive Networking
Receptions, hosted luncheons, and curated networking connect senior leaders far beyond the meeting table.
How partnering works
1
Platform opens
Four weeks before the event - activate your profile and browse verified delegates.
2
Filter & request
Target by asset, capacity, or capability and send your meeting requests.
3
Meet in Zurich
Pre-scheduled 30-minute private meetings across three focused days.
Your next manufacturing partner is already in the room.
Register Now
Secure your pass to activate your partnering profile.
Featured Topics
The full scope of ADC manufacturing & commercialization
Twelve focus areas spanning the entire value chain - from bioconjugation and fill-finish to supply chain, automation, and commercial scale-up.
Commercial Manufacturing
Technology Transfer
Bioconjugation
CMC
Fill-Finish
Regulatory Affairs
Supply Chain
Digital Manufacturing
Quality Systems
Automation
Cold Chain
Continuous Manufacturing
Key Metrics & Audience Focus
The summit by the numbers
350+
Executive Delegates
30+
Global Speakers
40+
Solution Providers
25+
Countries
300+
Companies
Hundreds
Pre-Scheduled Business Meetings
The Audience
An elite, transaction-driven audience
100%
senior decision-makers
- 45% C-Suite, Vice Presidents & Global Heads
- 35% Directors & Heads of Department
- 20% Principal CMC Leads & Senior Legal / Regulatory Counsel
Who You'll Meet
A carefully balanced cross-section of the organizations shaping the ADC value chain - from molecule to market:
- Global Pharmaceutical Companies
- ADC Biotechnology Innovators
- CDMOs
- Fill-Finish Providers
- Equipment Manufacturers
- Automation Companies
- Cold Chain & Logistics
- Regulatory Agencies
- Technology Providers
- Engineering Firms
- Investors
2027 Sponsors
Meet the organizations moving ADC manufacturing forward
Our 2027 sponsor roster is currently being confirmed. This section will be updated as participating CDMOs, technology providers, and supply-chain partners are announced.
Explore sponsorship opportunities
Expected Participation From
- Top Pharmaceutical Companies
- Global CDMOs
- Technology Providers
- Engineering Companies
- Automation Providers
- Analytical Solution Providers